1. Home
  2. DVAX vs AMRC Comparison

DVAX vs AMRC Comparison

Compare DVAX & AMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • AMRC
  • Stock Information
  • Founded
  • DVAX 1996
  • AMRC 2000
  • Country
  • DVAX United States
  • AMRC United States
  • Employees
  • DVAX N/A
  • AMRC N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • AMRC Engineering & Construction
  • Sector
  • DVAX Health Care
  • AMRC Consumer Discretionary
  • Exchange
  • DVAX Nasdaq
  • AMRC Nasdaq
  • Market Cap
  • DVAX 1.7B
  • AMRC 1.5B
  • IPO Year
  • DVAX 2004
  • AMRC 2010
  • Fundamental
  • Price
  • DVAX $12.45
  • AMRC $23.04
  • Analyst Decision
  • DVAX Buy
  • AMRC Strong Buy
  • Analyst Count
  • DVAX 2
  • AMRC 10
  • Target Price
  • DVAX $23.00
  • AMRC $36.88
  • AVG Volume (30 Days)
  • DVAX 1.8M
  • AMRC 421.6K
  • Earning Date
  • DVAX 02-20-2025
  • AMRC 02-26-2025
  • Dividend Yield
  • DVAX N/A
  • AMRC N/A
  • EPS Growth
  • DVAX N/A
  • AMRC 13.70
  • EPS
  • DVAX 0.15
  • AMRC 1.00
  • Revenue
  • DVAX $260,810,000.00
  • AMRC $1,678,629,000.00
  • Revenue This Year
  • DVAX $21.64
  • AMRC $30.87
  • Revenue Next Year
  • DVAX $19.81
  • AMRC $11.01
  • P/E Ratio
  • DVAX $82.38
  • AMRC $23.03
  • Revenue Growth
  • DVAX N/A
  • AMRC 32.70
  • 52 Week Low
  • DVAX $9.74
  • AMRC $17.55
  • 52 Week High
  • DVAX $14.30
  • AMRC $39.68
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 41.74
  • AMRC 40.80
  • Support Level
  • DVAX $12.27
  • AMRC $23.27
  • Resistance Level
  • DVAX $12.74
  • AMRC $28.87
  • Average True Range (ATR)
  • DVAX 0.35
  • AMRC 1.44
  • MACD
  • DVAX -0.06
  • AMRC -0.06
  • Stochastic Oscillator
  • DVAX 37.39
  • AMRC 9.33

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About AMRC Ameresco Inc.

Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of revenue from the U.S. Regions segment.

Share on Social Networks: